Anti-TNF-alpha therapy does not modulate leptin in patients with severe rheumatoid arthritis.

摘要: OBJECTIVE The adipocytokine leptin regulates weight centrally and participates in the regulation of immune inflammatory responses. Chronic systemic inflammation is major importance development atherosclerosis rheumatoid arthritis (RA). In present study we investigated whether inflammation, obesity or both these characteristics are potential determinants circulating concentrations a group RA patients on periodical treatment with TNF-alpha-blocker-infliximab due to severe disease. We also assessed infusion infliximab may alter RA. METHODS 33 infliximab. Serum levels were determined immediately prior after infusion. RESULTS There was positive correlation between body mass index baseline serum level (rho=0.665, p<0.001). Apart from significant VCAM-1 (rho=0.349, p=0.04), no correlations age at time onset disease, disease duration, ESR CRP levels, DAS28, lipids, insulin sensitivity, adhesion molecules, resistin, adiponectin, ghrelin cumulative prednisone dose found. Leptin did not change upon (p=0.48). CONCLUSION TNF-alpha blocker treatment, unrelated activity but constitute manifestation adiposity. beneficial effect anti-TNF-alpha therapy cardiovascular mortality does seem be mediated by reduction leptin.